BioNexus Gene Lab Corp (BGLC): Nasdaq/NYSE listing notice — BioNexus Gene Lab regains Nasdaq minimum bid price compliance, avoids delisting

BioNexus Gene Lab Corp

Received Nasdaq Panel confirmation on Apr 30, 2025, that BGLC met $1.00 minimum bid price rule.
Stock closed at $1.00+ for required consecutive business days as of Apr 23, 2025.
Company plans to expand RNA diagnostics and specialty chemicals via Chemrex and MRNA Scientific.
Appointed new independent board members and formed internal audit function to strengthen governance.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioNexus Gene Lab Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 30, 2025, BioNexus Gene Lab Corp. (the “Company”) received a formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The Company was previously notified of non-compliance with the Bid Price Rule and appeared before the Panel pursuant to Docket No. NQ 7050C-24. As of April 23, 2025, the Company’s common stock had maintained a closing bid price of $1.00 or greater for the requisite number of consecutive business day

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-003114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.